dbo:abstract
- Alicaforsen (trade name Camligo) is an antisense oligonucleotide therapeutic that targets the messenger RNA for the production of human ICAM-1 receptor and is being developed for the treatment of acute disease flares in moderate to severe Inflammatory Bowel Disease (IBD). Alicaforsen inhibits ICAM-1 production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation. Hitherto, alicaforsen has been granted orphan drug designation and is prescribed as an unlicensed medicine in accordance with international regulation, for the treatment of pouchitis and left-sided ulcerative colitis. Given the positive results from an open-label trial and one case series in patients with chronic refractory pouchitis, US FDA has agreed to a rolling submission for a license application for the treatment of pouchitis. It was discovered by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) and in 2017 Atlantic Healthcare plc took over the development for chronic antibiotic refractory pouchitis in an enema formulation. (en)
dbp:stdinchi
- InChI=1S/C192H244N75O98P19S19/c1-76-40-256136-30-8911054-318-380359-92-33-139340-11256-320-373354-88-29-135336-10852-316-379363-96-37-144346-11862-326-384365-98-39-146344-11660-324-377358-91-32-138337-10953-317-371352-85-26-132335-10751-315-378362-95-36-143345-11761-325-383361-94-35-141342-11458-322-382360-93-34-140341-11357-321-372353-86-27-133332-10448-311-369350-83-24-130331-10347-310-368349-82-23-129329-10145-309-367347-80-21-142263-71-222-151-164235-177240-172273/h4-19,40-42,63-75,79-118,127-146,268-269H,20-39,43-62H2,1-3H3,/t79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?,376?,377?,378?,379?,380?,381?,382?,383?,384?/m0/s1 (en)
rdfs:comment
- Alicaforsen (trade name Camligo) is an antisense oligonucleotide therapeutic that targets the messenger RNA for the production of human ICAM-1 receptor and is being developed for the treatment of acute disease flares in moderate to severe Inflammatory Bowel Disease (IBD). It was discovered by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) and in 2017 Atlantic Healthcare plc took over the development for chronic antibiotic refractory pouchitis in an enema formulation. (en)